Clincosm LogoSign in Get a demo

TRANSCOV-19: Transfusion and COVID-19

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05075915
Collaborator
(none)
500
Enrollment
1
Location
16
Anticipated Duration (Months)
31.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure.

To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Transfusion and COVID-19
    Actual Study Start Date :
    Sep 1, 2020
    Anticipated Primary Completion Date :
    Dec 31, 2021
    Anticipated Study Completion Date :
    Dec 31, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020 [Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:

    • Adults patient (≥18 years old)

    • Patients admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020

    • Labile blood products consumed between February 24 and May 31 of 2019 and 2020

    • Subjects not having his opposition, after information, to the reuse of his data for the purposes of this research.

    Non-inclusion criteria:

    • Patients who expressed opposition to participating in the study

    • Patients under legal protection

    • Patients under guardianship or curatorship

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg Strasbourg France 67091

    Sponsors and Collaborators

    • University Hospital, Strasbourg, France

    Investigators

    • Principal Investigator: Paul-Michel MERTES, MD, PhD, Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Strasbourg, France
    ClinicalTrials.gov Identifier:
    NCT05075915
    Other Study ID Numbers:
    • 7958
    First Posted:
    Oct 13, 2021
    Last Update Posted:
    Dec 1, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Strasbourg, France
    COVID-19
    Blood donation
    Blood transfusion
    Labile products
    Blood platelets
    Psoralen
    ECMO
    SARS-CoV-2
    Consumption of blood products
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Dec 1, 2021